Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420611 | 0.92 | CACNA1H (0.49) | CACNA1HEPHX1DRD2MEN1GAA | |
| SCHEMBL13635148 | 0.86 | DRD2 (0.48) | CACNA1HEPHX1DRD2MEN1GAA | |
| SCHEMBL14599656 | 0.86 | CACNA1H (0.47) | CACNA1HEPHX1DRD2MEN1GAA | |
| SCHEMBL6007677 | 0.84 | SLC6A1 (0.46) | CACNA1HEPHX1DRD2MEN1KMT2A | |
| SCHEMBL6007685 | 0.84 | SLC6A1 (0.46) | CACNA1HEPHX1DRD2MEN1KMT2A | |
| SCHEMBL18233688 | 0.84 | DRD2 (0.46) | CACNA1HEPHX1DRD2MEN1GAA | |
| SCHEMBL13698623 | 0.83 | CACNA1H (0.43) | CACNA1HEPHX1DRD2MEN1GAA | |
| SCHEMBL24172673 | 0.82 | DRD2 (0.56) | CACNA1HEPHX1DRD2MEN1GAA | |
| SCHEMBL4024516 | 0.82 | DRD2 (0.56) | CACNA1HEPHX1DRD2MEN1GAA | |
| SCHEMBL31301250 | 0.82 | DRD2 (0.56) | CACNA1HEPHX1DRD2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858836-B1 | ANALOGUES OF THE AZINOMYCINS AS ANTI-TUMOUR AGENTS AND AS PRODRUGS | UNIV BRADFORD (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090233966-A1 | Analogues of the Azinomycins as Anti-Tumour Agents and as Prodrugs | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2009-09-17 | — | — | US | disclosed |
| US-20090233966-A1 | Analogues of the Azinomycins as Anti-Tumour Agents and as Prodrugs | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233966-A1 | Analogues of the Azinomycins as Anti-Tumour Agents and as Prodrugs | CYP1B1, AZI2, ECI1 | CACNA1H 3257/4885EPHX1 301/4885DRD2 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.